[ Price : $8.95]
FDA Webview closes its newsroom for the end-of-year Holiday Season, reopening Monday, Jan 5, 2026.[ Price : $8.95]
Sanofi says it will not seek FDA approval for tolebrutinib in primary progressive multiple sclerosis after the drug failed to meet...[ Price : $8.95]
FDA says it is removing a long-standing barrier to the use of real-world evidence in regulatory reviews by accepting such data wit...[ Price : $8.95]
FDA posts two final guidances that provide recommendations to help clinical investigators comply with the safety reporting require...[ Price : $8.95]
The Government Accountability Office urges HHS to shore up staffing and reassess legal authorities at FDA after finding significan...[ Price : $8.95]
FDA approves Daiichi Sankyos Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with Genentechs pertuzumab as a first-line t...[ Price : $8.95]
FDA posts updated guidance calling on drug and biologics developers to broaden eligibility criteria, modernize enrollment practice...[ Price : $8.95]
Vanda Pharmaceuticals files a BLA for imsidolimab and its use in treating generalized pustular psoriasis, a rare and potentially f...